SOD1 and Renal insufficiency: Likewise, Khabbazi et al., in a study conducted in patients with renal failure, who were given 600 mg/day of ALA for eight weeks, did not observe statistically significant changes in MDA and total antioxidant status levels [47]; Sharman et al., in a trial conducted in healthy adults, who were given 600 mg/day of ALA for seven days, also found no changes in the levels of MDA, SOD, GPx, and catalase [52]; and Ahmadi et al. also found no changes in MDA with the administration of 600 mg/day of ALA for two months in hemodialysis patients [53].